CTI BIOPHARMA CORP Quarterly Revenue from Contract with Customer, Excluding Assessed Tax in USD from Q2 2017 to Q1 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
-
Summary
-
Cti Biopharma Corp quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from Q2 2017 to Q1 2023.
- Cti Biopharma Corp Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending March 31, 2023 was $24.1M, a 951% increase year-over-year.
- Cti Biopharma Corp Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending March 31, 2023 was $75.8M, a 3201% increase year-over-year.
- Cti Biopharma Corp annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $53.9M.
- Cti Biopharma Corp annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $0.000.
- Cti Biopharma Corp annual Revenue from Contract with Customer, Excluding Assessed Tax for 2020 was $0.000, a 100% decline from 2019.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Growth (%)